On November 1, 2019 Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer, reported two oral presentations at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Checkmate Pharmaceuticals, NOV 1, 2019, View Source [SID1234550187]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Friday, November 8, 2019 at 12:15pm ET, Dr. John M. Kirkwood, professor of medicine, dermatology, and clinical and translational science at the University of Pittsburgh School of Medicine and the Clinical and Translational Science Institute at the University of Pittsburgh, will present late-breaking data from a Checkmate Sponsored Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy.

Title: Durable responses in anti-PD-1 refractory melanoma following intra-tumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab
Abstract #: 11548/O87

On Saturday, November 9, 2019 at 6:15pm ET, Dr. Diwakar Davar, an assistant professor of medicine at the University of Pittsburgh School of Medicine, will present data from his investigator-sponsored trial evaluating neoadjuvant treatment with CMP-001 in combination with nivolumab in Stage IIIB/C/D Melanoma.

Title: Phase II Trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high risk resectable melanoma (MEL): Preliminary Results
Abstract #: 11648/O34

About CMP-001

CMP‐001 is a first‐in‐class CpG‐A Toll‐like receptor 9 (TLR9) agonist that is encapsulated in a virus‐like particle. CMP‐001 is designed to induce both innate and adaptive anti‐tumor immune responses, thereby converting immunologically "cold" tumors into immunologically "hot" tumors, with the potential to mediate tumor regression. It is the only CpG‐A class TLR9 agonist in clinical trials and differs from other CpG classes in clinical development by having a native DNA backbone that induces the highest levels of type I Interferon (IFN). Based on analyses of gene expression in human tumors showing that increased IFN and related immune gene expression is associated with better response to PD‐1 inhibition, it is believed that this mechanism of action may restore, enable or improve responses to anti‐PD‐1/PD‐L1 therapeutics. CMP‐001 is being evaluated in multiple tumor types to assess safety, activity, alternative routes of administration and combination with other immunotherapies and modalities. For information on CMP‐001 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.